Despite questionable PARP data, FDA stamps quick OK on Lynparza as a frontline therapy for pancreatic cancer
FDA analysts picked apart the data, highlighted an absence of overall survival benefit and noted that AstraZeneca had yet to hit the mark required for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
